BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.28
+3.17%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.15
From 52W high−92.04%
Volume52821.00
Market cap$10.19M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.15
From 52W high
−92.04%
Volume
52821.00
Market cap
$10.19M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
87.1
MomentumView details →
1D Return
+3.17%
YTD Return
−14.04%
SummaryUpdated Jun 1, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a medical device company founded in 2015 and headquartered in Acton, Massachusetts. The company went public in November 2021 and focuses on developing point-of-care diagnostic solutions for healthcare providers. Bluejay operates in the early-stage medical diagnostics sector, developing innovative testing platforms designed to improve patient care through rapid, accurate diagnostic capabilities at the point of care.
Similar companies
Latest newsMore news →
Bluejay Diagnostics completed establishment of a manufacturing site for Symphony cartridges, meeting a contractual milestone under its amended license agreement with Toray Industries.22d agoBluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, covering 777 evaluable patients, as it advances the Symphony IL-6 Test toward regulatory submission.29d agoBluejay Diagnostics and Lovell Government Services announced a partnership to expand access to U.S. federal healthcare markets, establishing a federal distribution and co-marketing framework across VA, DoD, Military Health Systems and other government healthcare channels.57d ago